Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform you that the Board of Directors at their meeting held today (i.e. 28th May, 2026) which commenced at 03:00 P.M. and concluded at 05:00 P.M. have inter alia approved the following: ? The Board considered and approved the Audited Standalone Financial Results of the company along with the Auditors Report for the quarter and financial year ended 31st March, 2026 as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
With reference to the captioned subject and in compliance with Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the meeting of - the Board of Directors of M/s. Prism Medico and Pharmacy Limited (hereinafter referred as “the Company”) is scheduled to be held at the registered office of the company i.e. Suketi Road, Kala Amb, Sirmaur, Himachal Pradesh-173030 on Thursday, the 28 day of May, 2026 at 03:00 P.M. inter alia, to: - 2026, Consider, approve and take-on record the Audited Standalone Financial Results of the company along with the Auditors Report for the quarter and financial year ended 31st March, as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. - Consider and discuss any other routine matter or business of the company.
Dear Sir / Madam, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform you that the Board of Directors of the company at their meeting held today (i.e. 11th May, 2026) which commenced at 04:00 P.M. and concluded at 04:30 P.M. have inter alia approved the following: 1. To appoint Mr. Harpreet Singh of M/s. S Harpreet and Associates, Chartered Accountants, as internal auditors of the company for the financial year 2025-2026. You are requested to kindly take the same on your record and acknowledge receipt. Thanking You.
With reference to the subject cited, this is to inform the Exchange that the meeting of the Board of Directors of Prism Medico and Pharmacy Limited held on Tuesday, May 05, 2026 at the registered office of the Company, the following were considered and approved: 1. Allotment of 75,00,000 (Seventy Five Lacs) Equity Shares of face value of ?10/- each at an issue price of ?10/- (Rupees Ten Only) per Equity Share and 50,00,000 (Fifty Lacs) Convertible Warrants on a preferential basis, at an issue price of ?10/- (Rupees Ten Only) per Warrant, Convertible Warrants on Preferential Basis, in accordance with and pursuant to the special resolution passed by the Members of the Company at their Extra-ordinary General Meeting held on March 20, 2026 and In-Principle Approval received from BSE Ltd (Stock Exchange where the shares of the Company are listed) on March 25, 2026. The details of the allottees have been enclosed herewith.
With reference to the subject cited, this is to inform the Exchange that the meeting of the Board of Directors of Prism Medico and Pharmacy Limited held on Tuesday, May 05, 2026 at the registered office of the Company, the following were considered and approved: 1. Allotment of 75,00,000 (Seventy Five Lacs) Equity Shares of face value of ?10/- each at an issue price of ?10/- (Rupees Ten Only) per Equity Share and 50,00,000 (Fifty Lacs) Convertible Warrants on a preferential basis, at an issue price of ?10/- (Rupees Ten Only) per Warrant, Convertible Warrants on Preferential Basis, in accordance with and pursuant to the special resolution passed by the Members of the Company at their Extra-ordinary General Meeting held on March 20, 2026 and In-Principle Approval received from BSE Ltd (Stock Exchange where the shares of the Company are listed) on March 25, 2026. The details of the allottees have been enclosed herewith.
Dear Sir/Madam, Please find the attached confirmation regarding non-applicability of large corporate entity framework. You are requested to take the same on record and oblige. Thanks and Regards.
Dear Sir/Madam, Pursuant to Regulation 13(3) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, please find the attached certificate from the RTA for the quarter ended 31st March 2026. You are requested to kindly take the same on record and oblige. Thankyou.
Dear Sir/Madam, Pursuant to Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, please find the attached certificate issued by RTA for the quarter ended 31st March 2026. You are requested to kindly take the same on record and oblige. Thanking you.
Dear Sir/ Madam, Pursuant to Regulation 57(5) of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, please find attached the intimation. Kindly take the same on record and oblige. Thanking you.
Dear Sir/Madam, Pursuant to Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, please find attached the attached disclosure for your reference and record. Kindly take the same on record and oblige. Thanking you.
| Particulars | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 0.00 | 0.00 | 0.00 | 1.27 | 0.00 | 0.03 | 2.75 | 0.15 | 0.06 | 0.29 | 0.50 | 0.28 |
| YOY Revenue Growth % | - | - | - | -84.95% | - | - | - | -88.57% | - | 780.12% | -81.72% | 93.8% |
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.01 | 0.00 | 0.10 | 0.00 | 0.00 | 0.02 | 0.00 |
| Total Income | 0.00 | 0.00 | 0.00 | 1.27 | 0.02 | 0.04 | 2.75 | 0.24 | 0.06 | 0.29 | 0.52 | 0.28 |
| Total Expenses + | 0.08 | 0.02 | 0.03 | 1.25 | 0.11 | 0.10 | 2.56 | 0.31 | 0.15 | 0.28 | 0.60 | 0.41 |
| Cost of Materials Consumed | 0.00 | 0.00 | 0.00 | 1.14 | 0.00 | 0.05 | 2.40 | 0.11 | 0.05 | 0.24 | 0.45 | 0.22 |
| Employee Benefit Expense | 0.03 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.03 |
| Other Expenses | 0.05 | 0.01 | 0.02 | 0.10 | 0.10 | 0.04 | 0.15 | 0.19 | 0.09 | 0.03 | 0.13 | 0.16 |
| Operating Profit | -0.08 | -0.02 | -0.03 | 0.02 | -0.11 | -0.06 | 0.19 | -0.17 | -0.09 | 0.01 | -0.10 | -0.13 |
| OPM % | 0% | 0% | 0% | 1.9% | 0% | -198.5% | 6.9% | -116.5% | -145.9% | 3.5% | -20.2% | -44.5% |
| Profit Before Tax + | -0.08 | -0.02 | -0.03 | 0.03 | -0.09 | -0.05 | 0.19 | -0.07 | -0.09 | 0.01 | -0.08 | -0.12 |
| Tax Expense | 0.00 | 0.00 | 0.00 | -0.03 | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 | 0.12 |
| Tax % | - | - | - | -98% | - | - | 0% | - | - | 6% | - | - |
| Profit After Tax | -0.08 | -0.02 | -0.03 | 0.05 | -0.09 | -0.05 | 0.19 | -0.07 | -0.09 | 0.01 | -0.08 | -0.24 |
| EPS (Basic) | -0.01 | 0.00 | -0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.30 |
| Particulars | Mar 2026 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|
| Revenue from Operations | 2.44 | 2.93 | 1.27 | 8.44 | 16.76 |
| YOY Revenue Growth % | -16.47% | 130.22% | -84.95% | -49.63% | - |
| Other Income | 0.03 | 0.12 | 0.00 | 0.00 | 0.00 |
| Total Income | 2.47 | 3.05 | 1.27 | 8.44 | 16.76 |
| Total Expenses + | 2.04 | 3.08 | 1.37 | 8.94 | 16.94 |
| Cost of Materials Consumed | 1.57 | 2.56 | 1.14 | 10.55 | 21.47 |
| Employee Benefit Expense | 0.06 | 0.03 | 0.05 | 0.19 | 0.17 |
| Other Expenses | 0.40 | 0.47 | 0.18 | 0.12 | 0.09 |
| Operating Profit | 0.40 | -0.15 | -0.10 | -0.50 | -0.18 |
| OPM % | 16.5% | -5.1% | -8.2% | -5.9% | -1% |
| Profit Before Exceptional | 0.43 | -0.03 | -0.10 | -0.50 | -0.18 |
| Exceptional Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit Before Tax + | 0.43 | -0.03 | -0.10 | -0.50 | -0.18 |
| Tax Expense | 0.11 | -0.01 | -0.03 | -0.13 | -0.05 |
| Tax % | 25.9% | - | - | - | - |
| Profit After Tax | 0.32 | -0.02 | -0.08 | -0.37 | -0.13 |
| EPS (Basic) | 0.53 | 0.00 | -0.01 | -0.06 | -0.02 |
| Particulars | Mar 2026 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|
| ASSETS | |||||
| Non-Current Assets + | 0.15 | 0.25 | 0.25 | 0.23 | 205,215.37 |
| Property, Plant & Equipment | 0.03 | 0.03 | 0.04 | 0.05 | 5,534.09 |
| Capital Work in Progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Non-Current Investments | 0.00 | 0.00 | 0.00 | 0.00 | 193,800.00 |
| Goodwill | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Intangible Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Assets + | 15.46 | 14.99 | 15.14 | 12.34 | 1,948,990.59 |
| Inventories | 6.77 | 6.77 | 6.77 | 6.77 | 484,662.40 |
| Trade Receivables | 3.93 | 3.69 | 4.76 | 4.88 | 1,351,394.12 |
| Cash and Cash Equivalents | 0.06 | 0.08 | 0.10 | 0.06 | 8,413.29 |
| Current Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| LIABILITIES & EQUITY | |||||
| Total Equity | 15.41 | 15.14 | 15.16 | 12.55 | 1,292,594.44 |
| Equity Share Capital | 6.06 | 6.06 | 6.06 | 6.06 | 606,342.80 |
| Other Equity | 9.35 | 9.08 | 9.10 | 6.49 | 686,251.64 |
| Non-Current Liabilities | 0.00 | 0.03 | 0.00 | 0.00 | 0.00 |
| Current Liabilities | 0.20 | 0.07 | 0.23 | 0.02 | 861,611.52 |
| Total Liabilities | 0.20 | 0.10 | 0.23 | 0.02 | 861,611.52 |
| Particulars | Mar 2026 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|
| Cash from Operating Activities | 0.00 | -0.01 | 2.95 | -2.38 | -0.05 |
| Cash from Investing Activities | 0.00 | 0.00 | -2.91 | 2.35 | 0.02 |
| Cash from Financing Activities | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 |
| Net Increase/Decrease in Cash | 0.00 | -0.01 | 0.04 | -0.03 | -0.03 |